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Abstract: Normal tissue radiosensitivity is thought to be influenced by an individual’s genetic
background. However, the specific genetic variants underlying the risk of late skin reactions following
radiotherapy for breast cancer remain elusive. To unravel the genetic basis for radiation-induced
late skin toxicity, we carried out targeted next-generation sequencing of germline DNA samples
from 48 breast cancer patients with extreme late skin toxicity phenotypes, consisting of 24 cases
with grade 2–3 subcutaneous fibrosis and/or grade 2–3 telangiectasia (LENT-SOMA scales) and
24 controls with grade 0 fibrosis and grade 0 telangiectasia. In this exploratory study, a total of five
single-nucleotide variants (SNVs) located in three genes (TP53, ERCC2, and LIG1) reached nominal
levels of statistical significance (p < 0.05). In the replication study, which consisted of an additional
45 cases and 192 controls, none of the SNVs identified by targeted NGS achieved nominal replication.
Nevertheless, TP53 rs1042522 (G > C, Pro72Arg) in the replication cohort had an effect (OR per
C allele: 1.52, 95%CI: 0.82–2.83, p = 0.186) in the same direction as in the exploratory cohort (OR per
C allele: 4.70, 95%CI: 1.51–14.6, p = 0.007) and was found be nominally associated to the risk of
radiation-induced late skin toxicity in the overall combined cohort (OR per C allele: 1.79, 95%CI:
1.06–3.02, p = 0.028). These results raise the possibility of an association between TP53 rs1042522
and risk of radiation-induced late skin toxicity in breast cancer patients; however, large replication
studies are warranted for conclusive evidence.
Keywords: radiotherapy; breast cancer; radiosensitivity; late skin reactions; targeted next-
generation sequencing
1. Introduction
Adjuvant radiotherapy (RT) after conservative surgery for early-stage breast cancer
is well tolerated and effective in the majority of patients [1,2]. However, a significant
proportion of long-term survivors experience late RT-related complications that may de-
velop from six months to several years after radiation exposure [3]. Late adverse reactions
to radiotherapy are generally irreversible and include a wide spectrum of normal tissue
reactions, with subcutaneous fibrosis and telangiectasia being the most common late skin
complications of radiotherapy for breast cancer [4]. Ionizing radiation generates reactive
oxygen species that lead to localized inflammation, which ultimately evolves into a fibrotic
process characterized by increased collagen deposition, poor vascularity, and scarring [5].
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This leads to breast indurations and in some cases to a poor cosmetic outcome that may
have an impact on patients’ quality of life [6]. Factors affecting the risk of developing late
radiation-induced skin injuries include RT parameters, such as total dose given, irradiated
volume, dose fractionation, and treatment duration, as well as some patient characteristics,
such as their age and lifestyle [7,8].
In the last decade, there has been growing interest in the identification of genetic deter-
minants for adverse long-term effects of radiotherapy in breast cancer patients. Regarding
the development of subcutaneous fibrosis and telangiectasia following radiotherapy for
breast cancer, several candidate gene association studies have focused on the polymorphic
variants of genes involved in the generation of reactive oxygen species [9–14], DNA re-
pair and damage response [10–15], and fibroblast proliferation and migration [16–18], as
well as susceptibility genes for heritable telangiectasia-associated disorders [10,11,19–23].
Among the genetic variants reported to be significant in at least one study for the oc-
currence of radiation-induced late skin reactions of the breast are GSTA1 rs3957356 [9],
GSTP1 rs1695 [13,24], SOD2 rs4880 [25], eNOS rs1799983 [9], XRCC1 rs2682585 [14], TGFβ1
rs1800469 [16,21], TP53 rs1042522 [15], and ATM rs1801516 [22]. Despite a great amount of
work being carried out in the field of radiogenomics, no polymorphic gene variant has been
firmly established as a risk factor for radiation-induced late skin reactions in breast cancer
patients. This is at least partly because of a failure to replicate the genetic associations
identified in previous studies in independent patient cohorts. In addition, only a few
polymorphisms per gene are usually considered by candidate gene association studies,
leading to the possibility that other overlooked genetic variants may also contribute to the
risk of radiation-induced late skin toxicity in breast cancer patients.
In the present study, we hypothesized that common single-nucleotide variants (SNVs)
may influence the occurrence of subcutaneous fibrosis and telangiectasia after breast
irradiation for breast cancer. In order to unravel the genetic basis for radiation-induced
late skin toxicity and to overcome, at least in part, the limits of previous single candidate
gene association studies, we herein carried out the targeted next-generation sequencing
(NGS) of a large number of candidate genes on germline DNA samples from an exploratory
cohort group and, subsequently, genotyped the identified SNVs in a larger cohort of breast
cancer patients who received RT after undergoing breast-conserving surgery.
2. Materials and Methods
2.1. Setting and Participants
A total of 285 female Italian patients diagnosed with breast cancer and treated with
conservative surgery and adjuvant radiotherapy (RT) from 1989 to 2010 at the Department
of Radiation Oncology of the University Hospital “Maggiore della Carità” in Novara,
Italy, were enrolled in the present study. Radiotherapy was delivered in all patients
after planning computed tomography using a 3D technique through opposed tangential
6 MV X-ray beams for a total dose of 50 Gy with daily fractions of 2 Gy, followed by
9–10 Gy electron boosts in the case of invasive lesions. At the time of patient recruitment, a
peripheral blood sample was taken and stored at 4 ◦C until DNA extraction. The occurrence
of early and late toxicity was systematically assessed by an experienced radiation oncologist
at annual follow-up visits, with special attention given to telangiectasia and subcutaneous
fibrosis. The mean follow-up time in the overall cohort of breast cancer patients was
10.3 years (95%CI: 9.8–10.7 years). RT-induced late adverse skin reactions were scored
according to the Late Effects of Normal Tissue-Subjective Objective Management Analytical
(LENT-SOMA) scale [26], which allows grading breast side effects from 1 to 4. Breast cancer
patients who experienced grade ≥ 2 subcutaneous fibrosis and/or grade ≥ 2 telangiectasia
(LENT-SOMA scales) were referred to as the case group and compared with control group
patients with no or minimal late skin reactions of the breast (fibrosis or telangiectasia of
grade 0–1).
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2.2. DNA Extraction and Quality Control
Genomic DNA was extracted from whole blood using the QiaAmp DNA Mini Kit
(Qiagen, Milan, Italy) according to the manufacturer’s protocol or with the salting-out
method. The DNA concentration and purity were determined, respectively, by a Qubit 4.0 flu-
orometer (Thermo Fisher, Milan, Italy) and Nanodrop spectrophotometer (Thermo Fisher,
Milan, Italy). DNA integrity was evaluated using the Agilent Genomic ScreenTape as-
say (Agilent Technologies, Milan, Italy) on the Agilent TapeStation 4200 system (Agilent
Technologies, Milan, Italy).
2.3. NGS Library Preparation, Sequencing, and Data Analysis
Illumina sequencing libraries were prepared using the SureSelect XT HS2 DNA sys-
tem (Agilent Technologies, Milan, Italy) according to the manufacturer’s instructions. The
MiSeq System (Illumina, Inc., San Diego, CA, USA) was used for the NGS of a custom panel
consisting of 55 genes involved in cell cycle, DNA damage repair, reactive oxygen species
pathway, and encoding for profibrotic and inflammatory cytokines (Appendix A, Table A1).
A secondary analysis of the sequences obtained was performed using the MiSeq Reporter
software (v. 2.6.2.3, Illumina, Inc., San Diego, CA, USA) and an integrated pipeline. FastQ
files were aligned to the reference genome (GRCh37/hg19) using BWA-MEM. The quality
trimming of the 3′ portion of reads with low-quality scores was performed. Duplicate
reads generated by PCR amplification during library preparation were removed using sam-
tools, and we performed the local realignment of reads around indels. Variant calling was
performed with the GATK software. As an acceptance quality threshold value for variant
calling, we selected a Q-score of 30, corresponding to a 1:1000 error rate. Genomic and func-
tional annotations of detected variants were made using wANNOVAR (WebANNOVAR,
http://wannovar.wglab.org/, accessed on 10 April 2021).
The mean depth for the sample set was 249× (range of mean depth for the various
patients: 210×–333×), with 99% of the target sequence being covered with >20 NGS reads
for each individual. To obtain the genotypes of the 48 samples for the detected variants,
the Variant Calling Format (VCF) files were converted into genotype calls using VCFtools.
To increase the precision of this phase, we merged the 48 VCF files of the various samples
into a single multi-sample VCF file. A typical VCF file only contains information about loci
for which at least one of the individuals presents with a non-reference allele; therefore, we
assumed patients presenting with 0 non-reference alleles for a variant to be homozygous
for the reference allele for that variant.
2.4. Real-Time PCR
The genotyping of the SNVs selected for the replication study was conducted in the
whole cohort of breast cancer patients in real-time PCR using Applied Biosystems TaqMan
Pre-Designed SNP Genotyping assays (rs1042522 Assay ID: C_2403545_10; rs13181 Assay
ID: C_3145033_10; rs1052555 Assay ID: C_3145034_10; rs7246696 Assay ID: C_189273455_10).
Real-time PCR amplification and detection were conducted in 96-well PCR plates using a
CFX Connect Real-Time PCR Detection System (Bio-Rad, Milan, Italy). Thermal cycling
was initiated with a denaturation step for 10 min at 95 ◦C, followed by 50 cycles of 15 s
at 92 ◦C and 90 s at 60 ◦C. After the PCR run was completed, allelic discrimination was
analyzed using the Bio-Rad CFX Manager Software (Version 3.1, Bio-Rad). Negative and
positive controls for the three genotypes were included in each real-time PCR run. For
validation purposes, approximately 10% of the samples were re-genotyped, and it was
found that the results were reproducible, with no discrepancies noticed in genotyping.
Genotyping was performed blinded to all clinical data.
2.5. Statistical Analysis
Categorical variables are reported as absolute (n) and relative frequencies (%), while
continuous variables are presented as means with standard deviation (SD). The Fishers’
exact test was first used to compare the number of reference alleles and variant alleles
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between cases/controls of the exploratory cohort. Univariate logistic regression analyses
were then performed to calculate the odds ratios (ORs) and the 95% confidence intervals
(CIs) for the association of SNVs with the risk of radiation-induced late skin toxicity,
assuming an additive genetic model of inheritance (i.e., that each variant allele has an
equal contribution to the outcome). To this purpose, genotypes from each SNV were coded
as 0, 1, or 2 according to their number of variant alleles, with each SNV modeled as a
continuous variable. Adjusted logistic regression analyses were also performed with the
inclusion of confounding clinical variables (p < 0.05 in the respective univariate logistic
regression analysis). Statistical analyses were performed using MedCalc software version
13.3.3 (MedCalc Software, Mariakerke, Belgium). The nominal significance threshold was
set at p < 0.05, while the Bonferroni-corrected p-value threshold for multiple testing was
set at 0.000048 (0.05/1046 SNVs) in the exploratory cohort or at 0.0125 (0.05/4 SNVs) in
the replication or combined cohort. Power calculations were performed using the Quanto
software (http://www.hydra.usc.edu/gxe/, accessed on 17 May 2021).
3. Results
3.1. Patients Characteristics
Detailed demographic, clinical, and RT data for the whole set of breast cancer patients
after stratification according to their radiosensitive status are shown in Table 1. Overall,
69 out of the 285 breast cancer patients (24.2%) experienced moderate or severe radiation-
induced late skin toxicity (grade 2–3 subcutaneous fibrosis and/or grade 2–3 telangiectasia,
LENT-SOMA scales), while 216 patients had minor late skin reactions of the breast (subcu-
taneous fibrosis or telangiectasia of grade 0–1). The univariate logistic regression analysis
revealed an association of age (OR 1.03; 95%CI, 1.00–1.06; p = 0.023) and BMI (OR 1.11;
95%CI, 1.03–1.19; p = 0.006) with a higher risk of late skin toxicity after radiation therapy
(Table 1). No other clinical factor was found to be significantly different between the two
groups of patients at p < 0.05 in the univariate analysis. The whole breast cancer population
was then divided into two groups of patients. The exploratory cohort included 24 cases,
randomly selected from those who experienced grade 2–3 subcutaneous fibrosis and/or
grade 2–3 telangiectasia, and 24 controls with grade 0 fibrosis and grade 0 telangiectasia.
The remaining breast cancer patients (n = 237) were included in the replication cohort,
consisting of 45 cases who experienced moderate or severe subcutaneous fibrosis or telang-
iectasia (grades 2–3) and 192 controls with minimal or no skin fibrosis or telangiectasia
(grades 0–1). There were no differences between the exploratory and replication cohorts
in terms of the patients’ characteristics (Supplementary Materials Table S1), except for
a higher percentage of current or former smokers in patients of the exploratory cohort
(27.1% vs. 12.7%, p = 0.020).
Table 1. Association analysis of clinical variables with radiation-induced late adverse skin reactions in the whole population
of breast cancer patients (n = 285).




n (%) OR (95% CI) p-Value
Age, years (SD) 60.8 (10.1) 60.0 (10.0) 63.2 (10.0) 1.03 (1.00–1.06) 0.023
BMI, mean (SD) 25.0 (3.8) 24.6 (3.8) 26.2 (3.7) 1.11 (1.03–1.19) 0.006
Breast diameter, cm (SD) 12.2 (2.6) 12.0 (2.6) 12.7 (2.6) 1.10 (1.00–1.22) 0.054
Breast CTV, cc (SD) 394.2 (530.0) 380.8 (586.5) 438.3 (270.4) 1.00 (1.00–1.00) 0.489
Follow-up, years (SD) 10.3 (4.0) 10.0 (3.9) 11.0 (4.2) 1.06 (0.99–1.13) 0.071
Diabetes mellitus
No 267 (93.7) 205 (94.9) 62 (89.9) 1 (reference)
Yes 18 (6.3) 11 (5.1) 7 (10.1) 2.10 (0.78–5.66) 0.140
Hypertension
No 211 (74.0) 155 (71.8) 56 (81.2) 1 (reference)
Yes 74 (26.0) 61 (28.2) 13 (18.8) 0.60 (0.30–1.16) 0.124
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Table 1. Cont.




n (%) OR (95% CI) p-Value
Vascular disease
No 263 (92.3) 200 (92.6) 63 (91.3) 1 (reference)
Yes 22 (7.7) 16 (7.4) 6 (8.7) 1.19 (0.45–3.17) 0.727
Tabagism
Never 242 (84.9) 181 (83.8) 61 (88.4) 1 (reference)
Current or former 43 (15.1) 35 (16.2) 8 (11.6) 0.68 (0.30–1.54) 0.354
Alcohol
No 276 (96.8) 209 (96.8) 67 (97.1) 1 (reference)
Yes 9 (3.2) 7 (3.2) 2 (2.9) 0.89 (0.18–4.39) 0.887
Postsurgical complications
None 239 (83.9) 176 (81.5) 63 (91.3) 1 (reference)
Seromas and hematomas 46 (16.1) 40 (18.5) 6 (8.7) 0.42 (0.17–1.04) 0.060
Neoadjuvant CT
No 278 (97.5) 210 (97.2) 68 (98.6) 1 (reference)
Yes 7 (2.5) 6 (2.8) 1 (1.4) 0.51 (0.06–4.35) 0.542
Adjuvant treatments
None 40 (14.0) 28 (13.0) 12 (17.4) 1 (reference)
CT 61 (21.4) 48 (22.2) 13 (18.8) 0.63 (0.25–1.57) 0.324
HT 131 (46.0) 100 (46.3) 31 (44.9) 0.72 (0.33–1.59) 0.420
CT + HT 53 (18.6) 40 (18.5) 13 (18.8) 0.76 (0.30–1.90) 0.556
Radiation quality
X-rays 263 (92.3) 199 (92.1) 64 (92.8) 1 (reference)
γ-rays 22 (7.7) 17 (7.9) 5 (7.2) 0.91 (0.32–2.58) 0.866
Dose/fraction
2 Gy 274 (96.1) 208 (96.3) 66 (95.7) 1 (reference)
1,8 Gy 11 (3.9) 8 (3.7) 3 (4.3) 1.18 (0.30–4.58) 0.809
Boost dose/fraction
3 Gy 72 (25.3) 58 (26.9) 14 (20.3) 1 (reference)
1.5–2 Gy 189 (66.3) 139 (64.4) 50 (72.5) 1.49 (0.76–2.90) 0.241
No boost 24 (8.4) 19 (8.8) 5 (7.2) 1.09 (0.35–3.43) 0.882
Acute skin toxicity, RTOG grade
0–1 196 (68.8) 151 (69.9) 45 (65.2) 1 (reference)
≥2 89 (31.2) 65 (30.1) 24 (34.8) 1.24 (0.70–2.20) 0.465
BMI, body mass index; CI, confidence interval; CT, chemotherapy; CTV, clinical target volume; OR, odds ratio; HT, hormone therapy; n,
number; RTOG, Radiation Therapy Oncology Group; SD, standard deviation.
3.2. Identification of Candidate Variants by Targeted Gene Sequencing
Targeted NGS sequencing was performed using the germline DNA of the breast
cancer patients included in the exploratory cohort (n = 48). After quality control (QC)
filtering of the raw sequencing data, 1046 SNVs were available for the comparison of allele
frequency between cases (n = 24) and controls (n = 24) for the exploratory cohort. Fisher’s
test revealed statistical differences at the significance level of 0.05 in the allele frequency
of five SNVs located in three genes (TP53, ERCC2, and LIG1), the details of which are
given in Table 2. In the univariate logistic regression analysis using an additive genetic
model (Table 3), a higher risk of radiation-induced late skin toxicity was detected for the
C allele of TP53 rs1042522 (OR per allele: 4.70, 95%CI: 1.51–14.6, p = 0.007), for the C allele
of TP53 rs1642785 (OR per allele: 4.70, 95%CI: 1.51–14.6, p = 0.007), for the T allele of
ERCC2 rs13181 (OR per allele: 4.78, 95%CI: 1.56–14.7, p = 0.006), for the G allele of ERCC2
rs1052555 (OR per allele: 4.75, 95%CI: 1.57–14.4, p = 0.006), and for the T allele of LIG1
rs7246696 (OR per allele: 2.81, 95%CI: 1.16–682, p = 0.022). These SNVs remained nominally
associated with the risk of radiation-induced late skin toxicity after adjustment for age and
BMI (Table 3). In the screened subjects, rs1042522 and rs1642785 of TP53 were found to be in
complete linkage disequilibrium (LD); therefore, only one of these (rs1042522) was selected
for genotyping by real-time PCR of patients included in the replication cohort. This choice
was also supported by the estimation of LD between these two variants for the Italian
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Tuscan population (TSI, D’: 1, r2 = 0.98) through using the LDlink website tool (available at
https://ldlink.nci.nih.gov/?tab=home, accessed on 13 April 2021). The comparison of
genotypes determined by targeted NGS and real-time PCR revealed no discrepancies in
the results of patients included in the exploratory study for the four SNVs selected for
replication (rs1042522, rs13181, rs1052555, rs7246696).
Table 2. Single-nucleotide polymorphisms identified by target sequencing for association with radiation-induced late
adverse skin reactions (SOMA-LENT scales) in the exploration cohort of breast cancer patients (n = 48).
Gene Chr SNP BP Region Ref (Allele 1)/Alt (Allele 2)
RAF Grade 0/
RAF Grade ≥ 2 p-Value * Risk Allele
TP53 17 rs1042522 7579472 Exonic(p.Pro72Arg) G/C 0.40/0.15 0.011 C
TP53 17 rs1642785 7579801 UTR5 G/C 0.40/0.15 0.011 C
ERCC2 19 rs13181 45854919 Exonic(p.Lys751Gln) G/T 0.50/0.23 0.010 T
ERCC2 19 rs1052555 45855524 Exonic(p.Asp711Asp) A/G 0.44/0.17 0.007 G
LIG1 19 rs7246696 48673212 Intronic C/T 0.56/0.31 0.023 T
* p-values are from Fisher’s test. Alt, alternative allele; BP, base position based on GrCh37/hg19 assembly; Chr, chromosome; RAF, reference
allele frequency; Ref, reference allele.
Table 3. Association analysis between SNVs identified by targeted NGS and risk of radiation-induced late adverse skin












Exploratory 3/13/8 0/7/17 4.70 (1.51–14.6) 0.007 4.23 (1.25–14.4) 0.021
Replication 7/74/111 2/11/32 1.52 (0.82–2-83) 0.186 1.27 (0.68–2.39) 0.456
Combined 10/87/119 2/18/49 1.79 (1.06–3.02) 0.028 1.54 (0.90–2.63) 0.111
ERCC2 rs13181
Exploratory 5/14/5 0/11/13 4.78 (1.56–14.7) 0.006 4.14 (1.27–13.4) 0.018
Replication 24/83/85 10/22/13 0.60 (0.38–0.96) 0.031 0.61 (0.38–0.97) 0.036
Combined 29/97/90 10/33/26 0.90 (0.61–1.33) 0.595 0.90 (0.60–1.4) 0.598
ERCC2 rs1052555
Exploratory 4/13/7 0/8/16 4.75 (1.57–14.4) 0.006 4.09 (1.30–12.9) 0.016
Replication 22/81/89 9/20/16 0.67 (0.42–1.07) 0.093 0.64 (0.40–1.03) 0.064
Combined 26/94/96 9/28/32 1.02 (0.68–1.52) 0.922 0.98 (0.65–1.46) 0.916
LIG1 rs7246696
Exploratory 8/11/5 2/11/11 2.81 (1.16–6.82) 0.022 2.72 (1.09–6.80) 0.032
Replication 27/81/84 10/17/18 0.80 (0.51–1.24) 0.316 0.81 (0.51–1.28) 0.365
Combined 35/92/89 12/28/29 0.99 (0.68–1.45) 0.971 1.00 (0.68–1.47) 0.993
* Logistic regression analysis adjusted by age and BMI, under the additive genetic model.
3.3. Replication and Combined Cohort Analyses of SNVs Identified by Targeted NGS
In the univariate logistic regression analysis (Table 3), none of the four SNVs achieved
nominal replication with an effect in the same direction as in the exploratory study. Al-
though ERCC2 rs13181 displayed a nominal significance in the replication cohort (p = 0.031),
the effect of the T allele of rs13181 was in the opposite direction as that shown in the ex-
ploratory study (OR per T allele: 0.60, 95%CI: 0.38–0.96). Conversely, TP53 rs1042522 was
found to have an effect (OR per C allele: 1.52, 95%CI: 0.82–2.83, p = 0.186) in the same
direction as that shown in the exploratory study and to be nominally associated with
the risk of radiation-induced late skin toxicity in the overall combined cohort (OR per
C allele: 1.79, 95%CI: 1.06–3.02, p = 0.028). However, the nominal association of TP53
rs1042522 in the overall combined cohort was lost after correction for multiple testing or
after adjustment for age and BMI (OR per C allele: 1.54, 95 CI: 0.90–2.63, p = 0.111, Table 3).
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4. Discussion
In the present study, we employed a targeted NGS panel of 55 candidate genes in an
exploratory cohort of breast cancer patients to identify common genetic variants associated
with the risk of radiation-induced late skin adverse reactions; subsequently, we attempted
to replicate the nominal associations in a larger cohort of breast cancer patients. Although
some SNVs were identified by targeted NGS to exhibit a nominal level of significance, none
of these associations achieved replication in the validation cohort or remained significant
after correction for multiple testing or adjustment for clinical covariates. Despite these
negative findings, the present study provides some methodological clues for the design of
future radiogenomic studies.
Our failure to replicate the findings of the exploratory cohort may be due to the use of
an insufficient sample size for the replication cohort or, alternatively, to the overestimation
of true genetic effects in the exploratory study, a phenomenon known as the “winner’s
curse”, which represents one of the major factors contributing to the failures of many
attempted replication studies [27,28]. Given the sample size of 45 cases and 192 controls
used for our replication cohort and assuming a power of 80% and a nominal level of
significance of 0.05, the minimal detectable odds ratio under the additive model of inheri-
tance for the replicated SNVs (minor allele frequency (MAF) from the exploratory cohort:
0.27 to 0.42) was 2.0. Thus, the sample size of our replication cohort could be sufficient
for the replication of the detected SNVs, with their ORs in the exploratory cohort being
between 2.81 and 4.78. On the other hand, we cannot exclude a possible overestimation
of the true genetic effects in our exploratory cohort given that breast cancer patients with
late skin adverse reactions of grade 1 were included in the replication cohort but not in
the exploratory cohort. Although the comparison of patient groups with the most extreme
phenotypes may have been a useful approach to identify gene variants most likely asso-
ciated with the endpoint of interest, this may have led to the overestimation of the true
genetic effects. Despite a possible winner’s curse effect in our exploratory study, in the
overall combined cohort, TP53 rs1042522 was found to be nominally associated with the
risk of radiation-induced late skin toxicity using a crude (unadjusted) logistic regression
analysis. Even though this result may be suggestive for a putative role of TP53 rs1042522 in
the development of radiation-induced late skin toxicity, the significance of this association
was lost after correction for multiple testing or adjustment for clinical covariates. Therefore,
further studies using larger cohorts of breast cancer patients are required in order to clarify
the effect of TP53 rs1042522 on normal tissue radiosensitivity and to take into account the
potential confounding effect of clinical factors.
The TP53 gene encodes for p53, a multi-functional transcription factor involved in
the induction of apoptosis, regulation of cellular proliferation, and maintenance of DNA
integrity in response to genotoxic stress, including ionizing radiation [29]. The polymorphic
variant rs1042522 (G > C, p.Pro72Arg) maps in the proline-rich domain of the TP53 gene,
resulting in the substitution of a proline with an arginine at codon 72. The Pro/Arg allelic
residues of TP53 rs1042522 have been shown to differ biochemically and biologically,
leading to different levels of apoptosis [30], as well as to different effects on cell cycle
progression [31] and the activation of DNA-repair genes [32]. To date, few studies have
investigated the role of TP53 rs1042522 as a genetic predictor of normal tissue responses
to radiation therapy in breast cancer patients; however, inconclusive results have been
reported [15,33,34]. Specifically, in the study of Chang-Claude et al. [15], breast cancer
patients carrying the rs1042522C allele were found to be at higher risk of telangiectasia
compared to non-carriers, a finding that is in line with our results, while in the study
of Tan et al. [33], no association was reported between TP53 rs1042522 and acute skin
toxicity, although a trend towards decreased risk was found for carriers of the rs1042522C
allele in normal-weight women. Besides TP53 rs1042522, two SNVs in ERCC2 (rs13181,
rs1052555) and LIG1 rs7246696 reached a nominal level of statistical significance in our
exploratory study, but these genetic variants were neither confirmed in the replication
cohort nor found to be associated with the risk of radiation-induced late skin toxicity in the
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whole population of breast cancer patients. ERCC2 encodes for the protein excision repair
cross-complementing 2 (also known as xeroderma pigmentosum group D (XPD)), which
acts as an essential component of the general transcription factor IIH (TFIIH) complex [35].
In turn, TFIIH plays a crucial role in the nucleotide excision repair (NER) pathway, which
is involved in the repair of a wide range of DNA lesions, including ionizing radiation-
induced oxidative damage and bulky DNA adducts [36]. rs13181 and rs1052555 of ERCC2
are exonic SNVs, the former being located in exon 23 and consisting of a lysine substitution
to a glutamine at position 751 (T > G, p.Lys751Gln) and the latter being a synonymous
variant (G > A, p.Asp711Asp). While no data exist on the impact of rs1052555 on normal
tissue radiosensitivity, the rs13181T allele (Lys 751) has been reported to lead to the sub-
optimal repair of X-ray-induced DNA damage [37], but no impact of ERCC2 rs13181 has
been reported in breast cancer patients in relation to the risk of radiation-induced acute
skin reaction [38]. On the other hand, the LIG1 gene encodes for DNA ligase 1, which is
an enzyme involved in DNA replication and base excision repair [39], and rs7246696 is an
intronic variant located in the transcription factor binding site that is potentially able to
influence the binding affinity of transcription factors [40].
The findings of the present study should be interpreted in light of the following
limitations and considerations. First, a targeted gene NGS panel was used in the exploratory
cohort; thus, we cannot exclude the possibility that some relevant genes may have been
overlooked because of our limited knowledge of the genes involved in the radiation
response. In addition, our exploratory cohort is limited in terms of sample size; thus,
it is substantially underpowered in terms of its ability to detect associations with small
genetic effect sizes. To overcome both these limitations, an approach based on whole-exome
sequencing should be considered by future radiogenomic studies in order to identify the
genetic determinants of normal tissue radiosensitivity in a larger exploratory cohort of
cancer patients. Third, we failed to replicate the findings of the exploratory study. Again,
this might reflect the low statistical power of the replication cohort, but we could not
exclude the possibility that an overestimation of the true genetic effects occurred in our
discovery cohort. Nevertheless, we would have expected that the effects of the SNVs
selected for replication would occur in the same direction in both the exploratory and
replication cohorts, while the effect of ERCC2 rs13181T allele in the two cohorts occurred
in the opposite direction. Finally, the nominal association of TP53 rs1042522 in the overall
combined cohort was lost after adjustment for clinical covariates. Thus, future studies using
larger cohorts of breast cancer patients are warranted in order to clarify the role of TP53
rs1042522 as a genetic determinant of radiation-induced late skin toxicity. If confirmed, our
results may pave the way to tailored radiotherapy strategies in breast cancer patients at
higher risk of local recurrence but at lower risk of late skin toxicity, including modification
of total dose and fractionation, as well as intensification of radiotherapy boost on the tumor
bed. In addition, further ongoing studies will help clarify whether rare low-frequency
variants with a major pathogenic role occurring in this gene panel might be involved in
radiation-induced late skin toxicity.
In conclusion, the results obtained for the whole breast cancer cohort suggest a possi-
ble association between TP53 rs1042522 and the risk of radiation-induced late skin toxicity
in breast cancer patients. However, the failure to confirm the association of TP53 rs1042522
within the replication cohort and the loss of its statistical significance in the overall popula-
tion after correction for multiple testing or adjustment for clinical confounders indicate
that we should consider this result as preliminary evidence requiring confirmation in
larger cohorts of breast cancer patients. Nonetheless, our findings clearly indicate that
radiogenomic studies with a two-phase design should be considered to prevent any further
reports of false-positive genetic associations.
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Appendix A
Table A1. List of genes selected for targeted next-generation sequencing.
Pathway Function Genes
Cell cycle BAX, CDKN1A, CHEK1, CHEK2, ESPL1, RAD9A
DNA damage repair: BER APEX1, APEX2, LIG3, OGG1, PNKP, XRCC1
DNA damage repair: DR MGMT
DNA damage repair: MMR MLH1, MSH2, MSH3, MSH6, PMS2, SSBP1
DNA damage repair: NER ERCC1, ERCC2, ERCC3,ERCC4, ERCC5, ERCC6, ERCC8, LIG1, PCNA
DSB detection MRE11A, NBN, RAD50
DSB repair: HR BRCA1, BRCA2, RAD51,RAD51C, XRCC2, XRCC3
DSB repair: NHEJ LIG4, PRKDC, XRCC4,XRCC5, XRCC6
DSB signal transduction ATM, ATR, TP53, TP53BP1
Profibrotic and inflammatory cytokines ACVRL1, IL12RB2, TGFB1,TNF-α, IL-6
Reactive oxygen species pathway GSTA1, GSTP1, NOS3, SOD2
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